BrightGene Historical Income Statement

688166 Stock

29.55 0.68 2.36%

Historical analysis of BrightGene Bio income statement accounts such as Interest Income of 21.7 M, Interest Expense of 53.6 M or Selling General Administrative of 74.7 M can show how well BrightGene Bio Medical performed in making a profits. Evaluating BrightGene Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BrightGene Bio's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining BrightGene Bio Medical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BrightGene Bio Medical is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrightGene Bio Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About BrightGene Income Statement Analysis

BrightGene Bio Medical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BrightGene Bio shareholders. The income statement also shows BrightGene investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

BrightGene Bio Income Statement Chart

At present, BrightGene Bio's Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 53.6 M, whereas Tax Provision is forecasted to decline to about 14.9 M.

Tax Provision Selling General Administrative Total Revenue Gross Profit

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Total Revenue

Total revenue comprises all receipts BrightGene Bio Medical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of BrightGene Bio Medical minus its cost of goods sold. It is profit before BrightGene Bio operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from BrightGene Bio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BrightGene Bio Medical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrightGene Bio Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2022	2023	2024	2025 (projected)
Gross Profit	641.0M	658.1M	756.8M	438.0M
Total Revenue	1.0B	1.2B	1.4B	751.2M

Gross Profit Total Revenue

BrightGene Bio income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Net Income	Income Tax Expense	Ebitda	Reconciled Depreciation	Minority Interest
Tax Provision		-0.58	0.49	0.75	0.87	0.89	0.76	0.92	0.94	0.91	0.81	0.83	0.84	0.95	0.94	0.85	0.9	0.65	0.66
Net Interest Income	-0.58		-0.73	-0.9	-0.76	-0.77	-0.84	-0.7	-0.64	-0.71	-0.81	-0.74	-0.78	-0.63	-0.69	-0.83	-0.76	-0.89	-0.96
Interest Income	0.49	-0.73		0.66	0.72	0.7	0.64	0.66	0.58	0.65	0.76	0.75	0.74	0.58	0.61	0.86	0.68	0.94	0.85
Selling General Administrative	0.75	-0.9	0.66		0.91	0.92	0.91	0.86	0.8	0.88	0.93	0.9	0.92	0.8	0.85	0.85	0.92	0.83	0.87
Total Revenue	0.87	-0.76	0.72	0.91		1.0	0.93	0.99	0.95	0.99	0.98	0.99	1.0	0.95	0.97	0.92	0.99	0.84	0.79
Gross Profit	0.89	-0.77	0.7	0.92	1.0		0.94	0.99	0.96	0.99	0.98	0.98	0.99	0.96	0.98	0.92	0.99	0.84	0.8
Other Operating Expenses	0.76	-0.84	0.64	0.91	0.93	0.94		0.9	0.86	0.89	0.95	0.9	0.93	0.85	0.89	0.84	0.9	0.8	0.81
Operating Income	0.92	-0.7	0.66	0.86	0.99	0.99	0.9		0.99	1.0	0.95	0.97	0.97	0.99	1.0	0.91	0.99	0.79	0.74
Net Income From Continuing Ops	0.94	-0.64	0.58	0.8	0.95	0.96	0.86	0.99		0.98	0.9	0.93	0.93	1.0	1.0	0.88	0.96	0.74	0.68
Ebit	0.91	-0.71	0.65	0.88	0.99	0.99	0.89	1.0	0.98		0.96	0.98	0.98	0.98	0.99	0.9	0.99	0.79	0.73
Research Development	0.81	-0.81	0.76	0.93	0.98	0.98	0.95	0.95	0.9	0.96		0.97	0.99	0.9	0.93	0.91	0.97	0.87	0.84
Cost Of Revenue	0.83	-0.74	0.75	0.9	0.99	0.98	0.9	0.97	0.93	0.98	0.97		1.0	0.93	0.95	0.9	0.98	0.84	0.77
Total Operating Expenses	0.84	-0.78	0.74	0.92	1.0	0.99	0.93	0.97	0.93	0.98	0.99	1.0		0.93	0.96	0.91	0.99	0.85	0.81
Income Before Tax	0.95	-0.63	0.58	0.8	0.95	0.96	0.85	0.99	1.0	0.98	0.9	0.93	0.93		1.0	0.88	0.96	0.73	0.68
Net Income	0.94	-0.69	0.61	0.85	0.97	0.98	0.89	1.0	1.0	0.99	0.93	0.95	0.96	1.0		0.9	0.98	0.77	0.73
Income Tax Expense	0.85	-0.83	0.86	0.85	0.92	0.92	0.84	0.91	0.88	0.9	0.91	0.9	0.91	0.88	0.9		0.92	0.95	0.92
Ebitda	0.9	-0.76	0.68	0.92	0.99	0.99	0.9	0.99	0.96	0.99	0.97	0.98	0.99	0.96	0.98	0.92		0.83	0.79
Reconciled Depreciation	0.65	-0.89	0.94	0.83	0.84	0.84	0.8	0.79	0.74	0.79	0.87	0.84	0.85	0.73	0.77	0.95	0.83		0.96
Minority Interest	0.66	-0.96	0.85	0.87	0.79	0.8	0.81	0.74	0.68	0.73	0.84	0.77	0.81	0.68	0.73	0.92	0.79	0.96

Click cells to compare fundamentals

BrightGene Bio Account Relationship Matchups

BrightGene Bio income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Tax Provision	22.0M	19.9M	30.8M	15.3M	17.6M	14.9M
Net Interest Income	6.3M	(10.4M)	(22.8M)	(26.7M)	(24.1M)	(22.9M)
Interest Income	9.5M	909.7K	2.2M	18.0M	20.7M	21.7M
Interest Expense	2.0M	9.7M	23.7M	44.4M	51.1M	53.6M
Selling General Administrative	47.5M	90.8M	123.2M	121.8M	140.1M	74.7M
Total Revenue	785.4M	1.1B	1.0B	1.2B	1.4B	751.2M
Gross Profit	431.4M	591.7M	641.0M	658.1M	756.8M	438.0M
Other Operating Expenses	3.1M	2.4M	4.2M	5.2M	6.0M	3.6M
Operating Income	208.3M	274.4M	264.7M	253.6M	291.6M	177.2M
Net Income From Continuing Ops	169.4M	237.6M	211.4M	173.4M	199.4M	142.9M
Ebit	107.9M	183.1M	249.2M	231.4M	266.1M	147.1M
Research Development	140.8M	173.3M	207.0M	248.6M	285.9M	154.7M
Cost Of Revenue	354.0M	460.7M	376.3M	521.4M	599.6M	313.2M
Total Operating Expenses	577.1M	778.0M	752.7M	925.9M	1.1B	574.0M
Income Before Tax	191.3M	257.5M	242.2M	188.8M	217.1M	157.7M
Net Income Applicable To Common Shares	111.1M	169.9M	244.0M	239.6M	275.6M	141.5M
Net Income	169.9M	244.0M	239.6M	202.5M	232.8M	151.7M
Income Tax Expense	8.9M	22.0M	19.9M	30.8M	35.4M	37.2M
Ebitda	146.3M	223.6M	308.6M	316.4M	363.8M	213.0M
Reconciled Depreciation	30.2M	41.5M	50.5M	78.1M	89.8M	94.3M

Currently Active Assets on Macroaxis

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin
ADA	Cardano
XRP	XRP

Other Information on Investing in BrightGene Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BrightGene Historical Income Statement

About BrightGene Income Statement Analysis

BrightGene Bio Income Statement Chart

Tax Provision

Total Revenue

Gross Profit

BrightGene Bio income statement Correlations

BrightGene Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BrightGene Bio income statement Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in BrightGene Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Total Revenue
Ebit	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Net Income From Continuing Ops

Minority Interest	- 0.96	Net Interest Income
Selling General Administrative	- 0.9	Net Interest Income
Reconciled Depreciation	- 0.89	Net Interest Income
Other Operating Expenses	- 0.84	Net Interest Income
Income Tax Expense	- 0.83	Net Interest Income
Research Development	- 0.81	Net Interest Income